Page 7 of 7
ACS Medicinal Chemistry Letters
1
2
3
4
5
6
7
8
recent developments. Expert Opin. Investigational Drugs 2011, 20
(6), 745 – 756.
Charo, I. F.; Ransohoff, R. M. The many roles of chemokines
and chemokine receptors in inflammation. N. Engl. J. Med. 2006, 354
its diprotonated, monoprotonated and unprotonated states.
Potentiometric titration reveals pKa values of 9.5 (tertiary amine) and
4.5 (quinazoline). Figure 4 considers only the equilibrium between
monoprotonated and unprotonated states, in which the
monoprotonated form (i.e. protonated tertiary amine) will dominate at
physiological pH.
10
(6), 610 – 621.
11
Feria, M.; Díaz-González, F. The CCR2 receptor as a
23
Zheng, Y.; Liu, X.; Samoshina, N. M.; Samoshin, V. V.; Franz,
therapeutic target. Exp. Opin. Ther. Patents 2006, 16 (1), 49 – 57.
12
A. H.; Guo, X. Fliposomes: trans-2-aminocyclohexanol-based
amphiphiles as pH-sensitive conformational switches of liposome
membrane - a structure-activity relationship study. Chem. Phys.
Lipids 2018, 210, 129 – 141.
Leuschner, F.; Dutta, P.; Gorbatov, R.; Novobrantseva, T. I.;
Donahoe, J. S.; Courties, G.; Lee, K. M.; Kim, J. I.; Markmann, J. F.;
Marinelli, B.; Panizzi, P.; Lee, W. W.; Iwamoto, Y.; Milstein, S.;
Epstein-Barash, H.; Cantley, W.; Wong, J.; Cortez-Retamozo, V.;
Newton, A.; Love, K.; Libby, P.; Pittet, M. J.; Swirski, F. K.;
Koteliansky, V.; Langer, R.; Weissleder, R.; Anderson, D. G.;
Nahrendorf, M. Therapeutic siRNA silencing in inflammatory
monocytes in mice. Nat. Biotechnol. 2011, 29 (11), 1005 – 1010.
13 Carter, P. H.; Brown, G. D.; Cherney, R. J.; Batt, D. G.; Chen, J.;
Clark, C. M.; Cvijic, M. E.; Duncia, J. V.; Ko, S. S.; Mandlekar, S.;
Mo, R.; Nelson, D. J.; Pang, J.; Rose, A. V.; Santella, J. B., 3rd;
Tebben, A. J.; Traeger, S. C.; Xu, S.; Zhao, Q.; Barrish, J. C.
Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC
Chemokine Receptors 2 and 5. ACS Med. Chem. Lett. 2015, 6 (4), 439
– 44.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
24
Knipe, P. C.; Thompson, S.; Hamilton, A. D. Ion-mediated
conformational switches. Chem. Sci. 2015, 6 (3), 1630 – 1639.
25
Thansandote, P.; Harris, R. M.; Dexter, H. L.; Simpson, G. L.;
Pal, S.; Upton, R. J.; Valko, K. Improving the passive permeability of
macrocyclic peptides: Balancing permeability with other
physicochemical properties. Bioorg Med Chem. 2015, 23 (2), 322 –
327.
26
Hewitt, W. M.; Leung, S. S.; Pye, C. R.; Ponkey, A. R.;
Bednarek, M.; Jacobson, M. P.; Lokey, R. S. Cell-permeable cyclic
peptides from synthetic libraries inspired by natural products. J. Am.
Chem. Soc. 2015, 137 (2), 715 – 721.
14
27
Cherney, R. J.; Mo, R.; Yang, M. G.; Xiao, Z.; Zhao, Q.;
Shalaeva, M.; Caron, G.; Abramov, Y. A.; O'Connell, T. N.;
Mandlekar, S.; Cvijic, M. E.; Charo, I. F.; Barrish, J. C.; Decicco, C.
P.; Carter, P. H. Alkylsulfone-containing trisubstituted cyclohexanes
as potent and bioavailable chemokine receptor 2 (CCR2) antagonists.
Bioorg. Med. Chem. Lett. 2014, 24 (7), 1843 – 1845.
Plummer, M. S.; Yalamanchi, G.; Farley, K. A.; Goetz, G. H.;
Philippe, L.; Shapiro, M. J. Integrating intramolecular hydrogen
bonding (IMHB) considerations in drug discovery using ΔlogP as a
tool. J. Med. Chem. 2013, 56 (12), 4870 – 4879.
15
28
Carter, P. H.; Cherney, R. J.; Batt, D. G.; Duncia, John V.;
Rossi Sebastiano, M.; Doak, B. C.; Backlund, M.;
Gardner, D. S.; Ko, S. S.; Srivastava, A. S.; Yang, M. G. Cyclic
derivatives as modulators of chemokine receptor activity. PCT Int.
Appl. WO 2005/021500; March 10, 2005.
Poongavanam, V.; Over, B.; Ermondi, G.; Caron, G.; Matsson, P.;
Kihlberg, J. Impact of Dynamically Exposed Polarity on Permeability
and Solubility of Chameleonic Drugs Beyond the Rule of 5. J. Med.
Chem. 2018, 61 (9), 4189 – 4202.
16 Meanwell, N. A. Improving Drug Design: An Update on Recent
Applications of Efficiency Metrics, Strategies for Replacing
Problematic Elements, and Compounds in Nontraditional Drug Space.
Chem. Res. Toxicol. 2016, 29 (4), 564 – 616.
29
Nielsen, D. S.; Hoang, H. N.; Lohman, R. J.; Hill, T. A.; Lucke,
A. J.; Craik, D. J.; Edmonds, D. J.; Griffith, D. A.; Rotter, C. J.;
Ruggeri, R. B.; Price, D. A.; Liras, S.; Fairlie, D. P. Improving on
nature: making a cyclic heptapeptide orally bioavailable. Angew.
Chem. Int. Ed. Engl. 2014, 53 (45), 12059 – 12063.
17
Yang, M. G.; Cherney, R. J.; Eastgate, M. G.; Muslehiddinoglu,
J.; Prasad, S. J.; Xiao, Z. Modulators of chemokine receptor activity,
crystalline forms and process. PCT Int. Appl. WO 2008/014381;
January 31, 2008.
18
Campbell, C. L.; Hassler, C.; Ko, S. S.; Voss, M. E.; Guaciaro,
M. A.; Carter, P. H.; Cherney, R. J. Enantioselective synthesis of
benzyl
(1S,2R,4R)-4-(tert-butoxycarbonylamino)-2-(hydroxyl-
methyl)cyclohexylcarbamate using an iodolactamization as the key
step. J. Org. Chem. 2009, 74 (16), 6368 – 6370.
19
Cherney, R. J.; Mo, R.; Meyer, D. T.; Voss, M. E.; Yang, M. G.;
Santella, J. B., 3rd; Duncia, J. V.; Lo,Y. C.; Yang, G.; Miller, P. B.;
Scherle, P. A.; Zhao, Q.; Mandlekar, S.; Cvijic, M. E.; Barrish, J. C.;
Decicco, C. P.; Carter, P. H. gamma-Lactams as glycinamide
replacements in cyclohexane-based CC chemokine receptor 2 (CCR2)
antagonists. Bioorg. Med. Chem. Lett. 2010, 20 (8), 2425 – 2430.
20
Deerberg, J.; Prasad, S. J.; Sfouggatakis, C.; Eastgate, M. D.;
Fan, Y.; Chidambaram, R.; Sharma, P.; Li, L; Schild, R.;
Müslehiddinoğlu, J.; Chung, H-J.; Leung, S.; Rosso, V.
Stereoselective Bulk Synthesis of CCR2 Antagonist BMS-741672:
Assembly of an All-cis (S,R,R)-1,2,4-Triaminocyclohexane (TACH)
Core via Sequential Heterogeneous Asymmetric Hydrogenations.
Organic Process Research & Development 2016, 20 (11), 1949 –
1966.
21
Zheng, Y.; Qin, L.; Zacarías, N. V.; de Vries, H.; Han, G. W.;
Gustavsson, M., Dabros, M.; Zhao, C.; Cherney, R. J.; Carter, P.;
Stamos, D.; Abagyan, R.; Cherezov, V.; Stevens, R. C.; IJzerman, A.
P.; Heitman, L. H.; Tebben, A.; Kufareva, I.; Handel, T. M. Structure
of CC chemokine receptor
2 with orthosteric and allosteric
antagonists. Nature 2016, 540, 458 – 461.
22 In aqueous solution, BMS-741672 exists in equilibrium between
6
ACS Paragon Plus Environment